TAMRA-conjugated DRL tripeptide for the visualization of synovium. (September 2022)

• Record Type: Journal Article
• Authors: Kim, Jaehoon; An, Jong Min; Kim, Youngwoong; Jin, Ji Hye; Kim, Sung Soo; Kang, Rae Hyung; Kim, Dokyoung
• Is Part Of: Dyes and pigments. Volume 205(2022)
• Publication Date: 2022-09
• Subjects: Synovium -- Targeting peptide -- Fluorogenic probe -- Peptide complex -- Fluorescence imaging; Dyes and dyeing -- Periodicals; Pigments -- Periodicals; 667.2
• DOI: 10.1016/j.dyepig.2022.110590
• Languages: English
• ISSNs: 0143-7208

Abstract

Abstract: The development of new cell-/organ-targeting peptides has been highlighted across various basic research fields and industries. In this work, a new synovium-homing tri-peptide, DRL, was developed through peptide screening and was functionalized to visualize the synovium via 5-carboxytetramethylrhodamine (TAMRA; TAM) conjugation. The TAMRA-conjugated DRL, named DRL-TAM, showed a bright red emission in cells and tissues with high biocompatibility (low cytotoxicity and biotoxicity). In the cell screening and in vivo fluorescence imaging studies, DRL-TAM demonstrated a remarkable visualization ability on the synovial-derived cells and synovial-related organs. DRL-TAM, as an advanced next generation of synovium-homing peptide, could open up new possibilities for the synovium-related disease diagnosis and treatment. Graphical abstract: Image 1 Highlights: A synovium-homing tri-peptide (DRL) and its TAMRA-conjugated formulation (DRL-TAM) are disclosed. DRL-TAM showed selective synovium visualization in vitro and in vivo. DRL-TAM displayed high biocompatibility.